High Throughput Screening of Active Ingredients in Drug Development
In Germany, 1.2 million people have dementia, two third of them suffering from the Alzheimer's disease. According to the current demographic development, the number of diseased persons will further increase in the next few years. The urgent need for new effective drugs to combat the Alzheimer's disease is obvious. This requires the analysis of potential active ingredients in numerous pre-clinical experiments.
- Development of a new high throughput test procedure for innovative drug development
- Development of a technology that rapidly, clearly and reliably forecasts active ingredients and forms of therapy for neuropathological diseases
- Design, development, construction, and testing of a functional model, which enables the simultaneous testing of up to 384 active ingredients during short or long-time measurements regarding their applicability against Alzheimer's disease